



Department of Defense Drug Demand Reduction Program (DDRP)

**Drug Testing Advisory Board Meeting
*May 20, 2016***

**COL Tom Martin, USA
Director, Drug Testing and Program Policy
Office of the Under Secretary of Defense for Personnel and Readiness
Personnel Risk Reduction**



DDRP Mission/Regulatory Guidance

- **Mission:**

- Deter illicit and prescription drug abuse by military service members and DoD civilian personnel in testing designated positions (TDPs) to maintain military readiness and safety
- Provide drug abuse prevention, education, and outreach services to military personnel and their families
- Identify new drugs of abuse entering the illicit drug culture and develop testing procedures to detect their use

- **Regulatory guidance is found in:**

- DODI 1010.01 Military Personnel Drug Abuse Testing Program
- DODI 1010.09 DoD Civilian Employee Drug-Free Workplace Program
- DODI 1010.16 Technical Procedures for the Military Personnel Drug Abuse Testing Program
- Executive Order 12564--Drug-Free Federal Workplace



DDRP Driving Factors

- Drug abuse in the general U.S. 18-25 year old male group is estimated to be 17-20%— the population from which the Service recruits their enlisted personnel
- Before DoD instituted drug testing among Service personnel, drug use was a significant recurring problem
 - Vietnam (estimated over 5% of returning service members addicted to heroin)
 - 1981 CVN Nimitz aviation mishap – 14 killed, 48 injured, 7 aircraft destroyed, 11 aircraft damaged, \$150M in damages, six deceased with detectable levels of marijuana
- Notable increase in abuse/misuse of prescription pain medications
- Personnel abusing illicit drugs or prescription medications are a safety hazard resulting in the potential loss of equipment, resources, and lives



DoD DDRP Leadership

**POLICY
ADVICE & GUIDANCE**

Secretary of Defense
HON Ashton Carter
Deputy Secretary of Defense
HON Robert Work

USD(Personnel & Readiness)
HON Peter Levine (Acting)

Executive Director Force Resiliency
Dr. Margaret Harrell

Director, PRR
Mr. Leonard Litton

EXECUTION

Secretary of the Army
HON Patrick Murphy (Acting)

Secretary of the Navy
HON Ray Mabus

Secretary of the Air Force
HON Deborah Lee James



DoD DDRP Leadership

**POLICY
ADVICE & GUIDANCE**

USD(Personnel & Readiness)
HON Peter Levine (Acting)

Executive Director Force Resiliency
Dr. Margaret Harrell

Director, PRR
Mr. Leonard Litton

Director, DDRP
COL Tom Martin

Accident Reduction

Risk Systems

BIOCHEMICAL TESTING ADVISORY BOARD (BTAB)

EXECUTION

Army Program Manager
LTC Karen McCart

Navy Program Manager
CDR Eric Welsh

Air Force Program Manager
Dr. Michael Hlubek

Chief, Forensic Toxicology, AFMES
CDR Tom Bosy



**QUALITY ASSURANCE
SPECIAL TESTING**



DDRP Responsibilities

- USD(P&R) Oversight of the Department of Defense (DoD) drug testing programs
 - Issues policy, directives, and guidance
 - Advocate for funding
 - Develops procedures and standards for drug testing laboratories
 - Maintain a certification and inspection program for DoD-certified drug testing laboratories
 - Establish Biochemical Testing Advisory Board (BTAB)



Military Services

- Operate forensic drug testing laboratories with sufficient capacity
 - Meet certification requirements
 - Participate in Quality Assurance program
 - Develop Medical Review Process
- Implement computerized, random selection



Chief, Division of Forensic Toxicology

Armed Forces Medical Examiner System (AFMES)

- Technical expertise to DDRP
- Manage external QC and proficiency testing programs
- Manage external QA program through Laboratory inspections
- Coordinate laboratory certification / recertification actions
- Evaluate all significant non-conforming events
- Serve as Chair of BTAB



BTAB Organization

- Advise Director, DDRP on technical and policy issues
- Two divisions
 - Technical (drug testing)
 - Personnel Policy
- Composition
 - Services' Technical and Personnel Program Representatives
 - Voting members
 - Military and/or civilian
 - Chair
 - Chief, FORTOX, AFMES
 - Non-voting member



BTAB Functions

- Methodologies and new technologies for drug testing
- External proficiency testing
- QA procedures
- Certification, decertification, recertification
- Addition/deletion to drug testing panel
- Policy changes
- Research projects
- Prevalence testing



BTAB Process

- Data driven decisions
- Minimize bureaucratic paperwork (“red tape”)
- Stepwise procedure
 - Objective data presented to BTAB from various sources
 - Surveillance testing
 - Literature review
 - Congressional interest
 - News Media reports, etc
 - Evaluate data and make decision recommendation to DDRP
 - Capability
 - Capacity
 - Cost
 - Policy change approved and implemented
 - DoD QA oversight




BTAB Process

- Rapid response to changing threat
- Prevalence testing
- Emerging synthetic drugs
 - “Spice” - Synthetic Cannabinoids
 - “Bath Salts” – Synthetic Cathinones / Phenethylamines
 - Supplement Additives
- Additions
 - Ecstasy, Oxycodone/Oxymorphone
 - Hydrocodone/Hydromorphone
 - Benzodiazepines
- Deletions
 - LSD
 - MDEA
 - Barbiturates




Adjusting the Testing Panel





DoD Laboratories





Current Panel of Tested Drugs

- Marijuana (THC)
- Cocaine (BZE)
- Amphetamine & Methamphetamine
- Designer Amphetamines / Ecstasy
- Heroin
- Oxycodone/Oxymorphone
- Hydrocodone/hydromorphone
- Codeine/Morphine (100% Opiates Testing on 1 Oct 2012)
- Benzodiazepines: nordiazepam, oxazepam, temazepam, lorazepam , and α -OH alprazolam (100% on 1 Oct 2013)
- Synthetic Cannabinoids (December 16, 2013)
- Special request for unusual or novel drug testing conducted at AFMES





DOD CUTOFFS

Screening (ng/mL)

• Amphetamines	500
• Cannabinoids	50
• Cocaine	150
• Opiates	300
• Designer Amps	500
• 6-AM	10
• Oxycodone	100
• Hydrocodone	300
• Benzodiazepines	200
• Synthetic cannabinoids	10

*Nordiazepam; Oxazepam; Temazepam;
Lorazepam; α -OH Alprazolam

**JWH18 COOH; JWH73 COOH;
UR144 COOH; MAM-2201; UR-144

Confirmation (ng/mL)

• d-Amphetamine	100
• d-Methamphetamine	100
• THC metabolite	15
• Benzoylecgonine	100
• Codeine	2,000
• Morphine	4,000
• MDMA/MDA	500
• 6-AM	10
• Oxycodone	100
• Oxymorphone	100
• Hydrocodone	100
• Hydromorphone	100
• Benzodiazepines*	100
• Synthetic cannabinoids**	1



Current Situation (Positive Drug Distribution)

- Changing pattern of synthetic cannabinoid use?

Unique Active Duty Positive Service Members	2010 (10,790)	2011 (8,988)	2012 (8,837)	2013 (8,948)	2014 (7,948)	2015 (7,067)
α-hydroxy-alprazolam (23% testing in FY 2013)	NT	NT	NT	40	120	131
Lorazepam (23% testing in FY 2013)	NT	NT	NT	13	63	40
Nordiazepam (23% testing in FY 2013)	NT	NT	NT	33	90	44
Oxazepam (23% testing in FY 2013)	NT	NT	NT	134	351	208
Temazepam (23% testing in FY 2013)	NT	NT	NT	92	256	154
JWH-018*	NT	NT	NT	NT	98	132
JWH-073*	NT	NT	NT	NT	106	120
UR-144*	NT	NT	NT	NT	131	49
MAM-2201*	NT	NT	NT	NT	NT	0
AB-CHMINACA*	NT	NT	NT	NT	NT	2
*40% testing in 2014 and 2015	--	--	--	--	--	--




Synthetic Marijuana (Spice)

- “Spice” products present unique challenges
 - Large number of Spice drug variants that are continually changing
 - Requires a low cost automated screening procedures to facilitate large population random testing
- DoD response
 - Random testing started December 16, 2013
 - 0.018 positive rate (similar to MDMA) in FY 2015
- Adding four metabolites May 2015
 - MAM-2201
 - AB-CHMINACA
 - AB-FUBINACA
 - AB-PINACA




Overall Military Positive Rate






Positive Rate by Component






Active Duty Positive Rate






Reserve Positive Rate





National Guard Positive Rate





DoD Agencies' Testing Results

FY	TDPs Tested	TDPs Positive	TDP Positive Rate	Applicants Tested	Applicants Positive	Applicant Positive Rate	Combined Positive Rate
2015	115536	393	0.34	40158	107	0.27	0.32
2014	116108	413	0.36	27845	77	0.28	0.34
2013	117041	443	0.38	24146	97	0.4	0.38
2012	114374	420	0.37	30295	121	0.4	0.37





Automated MRO Review Process

- Compares positive result to the individual's military prescription record
- Implemented on May 1, 2012
- Decreased manual MRO process (MRO "Wash")
- Tricare/DoD pharmacy dependent
- FY 2015 Summary
 - Oxycodone = 86% (12,586 positives "washed")
 - Benzodiazepines = 67% (11,838 positives "washed")
 - Amphetamine = 46% (11,443 positives "washed")

